Oncology - Medicines - HCP
Kisqali ribociclib logo
Oncology
KISQALI® (ribociclib)
SANDOSTATIN® LAR® (octreotide acetate) logo
Oncology
SANDOSTATIN® LAR® (octreotide acetate)
 TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) logo
Oncology
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in Non-Small Cell Lung Cancer (NSCLC)
 TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) logo
Oncology
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in melanoma

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.


Source URL: https://www.pro.novartis.com/uk-en/medicines/oncology